Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for LUPIN
Revenue projections for LUPIN

LUPIN's revenue projections show a decrease from last year, which tends to make investors more cautious. This could have a negative impact on the company's bottom line, as lower revenues typically suggest reduced profitability and growth potential, prompting concern among investors.

Financial Ratios:

currentRatio 0.000000
forwardPE 23.482035
debtToEquity 31.513000
earningsGrowth 0.373000
revenueGrowth 0.243000
grossMargins 0.705560
operatingMargins 0.264600
trailingEps 101.430000
forwardEps 98.471020

Lupin Limited's Forward PE being in a reasonable range suggests the stock is fairly priced based on its earnings. The stock isn't overpriced, leaving room for growth, making it an attractive investment for those seeking opportunities for future value appreciation.
LUPIN's positive earnings and revenue growth indicate that the company is well-positioned for business expansion. This growth suggests a strong financial trajectory, with LUPIN expected to continue increasing its profits and revenue in the coming periods.
Lupin Limited's positive gross and operating margins suggest strong profitability. These margins reflect effective cost management and revenue generation, indicating that the company is efficiently managing its operations and maintaining financial health.
LUPIN's lower forward EPS compared to trailing EPS suggests the company will likely experience reduced earnings in the current year. This may signal a less optimistic financial outlook.

Price projections:

Price projections for LUPIN
Price projections for LUPIN

Lupin Limited's price projections have been consistently revised upward, suggesting that analysts are becoming increasingly optimistic about the company's future. This trend reflects confidence in Lupin Limited's ability to achieve strong financial results.

Recommendation changes over time:

Recommendations trend for LUPIN
Recommendations trend for LUPIN


The analysts' recent buy bias for LUPIN indicates strong confidence in the stock's future performance. This could encourage more investors to view LUPIN as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.